Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs’ failure to improve motor function in a ...
The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results